Technology Transfer has committed over £434 million to translational projects across 94 institutions and in excess of 74 companies. On aggregate, over £806 million has been generated in third-party finance for these projects.
The types of project we support span computational chemistry to drug discovery, vaccine formulation and human proof-of-principle studies for medical devices, diagnostics and candidate pharmaceutical compositions. Therapeutic areas include cancer, the central nervous system, infectious diseases, inflammation, metabolism, tissue and wound healing.
The projects we have funded can be split broadly into the following areas:
- enabling technology
- regenerative medicine
- therapeutics (including Seeding Drug Discovery)
- medical devices
Health Innovation Challenge Fund
The Health Innovation Challenge Fund (HICF) is a parallel funding partnership between the Wellcome Trust and the Department of Health. The funders are collaborating to stimulate the creation of innovative healthcare products, technologies and interventions, and facilitate their development for the benefit of patients in the NHS and beyond. The HICF has a succession of thematic calls for proposals, each selected to focus on unmet needs in healthcare relevant to the NHS. The HICF offers translational funding to progress innovative approaches to healthcare from the proof-of-concept stage to early clinical studies in man. A number of projects have now been funded.